H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Voyager Therapeutics Inc (NASDAQ: VYGR) today and set a price target of $30. The company’s shares opened today at $23.
Chattopadhyay wrote:
“Our $30 price target is based on a 13-year DCF analysis leveraged solely to the prospects of VY- AADC in PD, which potentially leaves significant upside if the remainder of the pipeline matures favorably. Our DCF analysis is based on: beta of 1.41, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2027.”
According to TipRanks.com, Chattopadhyay is a 4-star analyst with an average return of 6.8% and a 51.4% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Voyager Therapeutics Inc is Strong Buy and the average price target is $31, representing a 34.8% upside.
In a report issued on June 6, Canaccord Genuity also maintained a Buy rating on the stock with a $35 price target.
See today’s analyst top recommended stocks >>
Based on Voyager Therapeutics Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $19.93 million. In comparison, last year the company had a GAAP net loss of $16.65 million.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
